F32 F33
Conditions
Interventions
Group 1: Lithium monotherapy. Initial dosage: 2x12,2 mmol/d p.o. Individual adaption to achieve serum levels between 0.6 and 0.8 mmol/L. Lithium serum level will be determined at days 3, 7, 14, 21 an
Sponsors
Klinik für Pschiatrie und Psychotherapie
Universitätsklinikums Carl Gustav Carus an der
Technischen Universität Dresden
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: diagnosis of a major depression according to DSM-IV, SCID I confirmed; at least 15 points on the Hamilton Rating Scale for Depression (21 item version); indication for a antidepressive pharmacotherapy independently of the study; oral and written informed consent; ability to give informed consent
Exclusion criteria
Exclusion criteria: manic or hypomanic episode in history (bipolar disorder); psychotropic medication within one wek prior to enrollment (one week wash out if neccessary); 20 mg/d diazepam or an equivalent dosage of another bezodiazepine are allowed prior and during the study; severe medical condition; conditions that contraindications to SSRIs or lithium or to the Dex/CRH test (e.g. severe renal dysfunction, severe cardial dysfunction, dysfunction of glucocorticoid or mineralocorticoid regulation); pregnancy; breast feeding; unsecure contraception; other axis I diagnoses beside the affective disorder; substance dependency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| area under the curve (AUC) for cortisol and for ACTH comparing AUCs before treatement with AUCs after four weeks of pharmacotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical efficacy as assessed by weekly ratings with the psychometric scales HAMD, BDI and CGI | — |
Countries
Germany
Contacts
Public ContactTom Bschor
Klinik für Pschiatrie und Psychotherapie des Universitätsklinikums Carl Gustav Carus an der Technischen Universität Dresden
Outcome results
None listed